Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT206 in Healthy Subjects
NCT07419698Phase 1Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Sarcopenia and muscle atrophy comparing JMT206 with Placebo group (2 arms). Primary endpoint: Adverse Events at 64 days. Started Jan 2026; status: recruiting.
02
Drugs
JMT206
03
Conditions
Sarcopeniamuscle atrophy
Beyond the preview
Go deeper on NCT07419698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419698.